Phloroglucinol Mylan is an antispasmodic agent that is commonly used for managing symptoms related to physical discomfort in conditions involving inflammatory or irritative processes. It contributes to easing the overall symptom load across domains where additional symptomatic support is needed.

The medicine is applied in areas where short-term symptom management is appropriate. Its main therapeutic focus is on providing supportive relief for acute or disruptive episodes associated with functional gastrointestinal and bile duct disorders, acute painful spasmodic urinary tract problems (such as renal colic), and painful spasmodic gynaecological conditions. It is considered relevant as a supportive measure during temporary contractions associated with pregnancy. This supportive use contributes to improved comfort during periods of heightened symptoms across these various conditions.

“This supportive relief helps maintain a sense of stability when symptoms are more noticeable, providing support that helps ease the overall symptom burden.”

Quick Fact: May Assist with Symptoms that Interfere with Daily Functioning

Regulatory References

1. Malta Medicines Authority Product Information

Who Can and Cannot Use Phloroglucinol Mylan? - Official Regulatory Information

The eligibility for using Phloroglucinol Mylan is determined by specific population restrictions, contraindications, and age limitations defined in regulatory documents.

Contraindicated Populations (Must Not Use)

Use of this medicine is contraindicated in patients with known hypersensitivity to phloroglucinol or any of its excipients. Due to formulation components, it must not be used by patients with Phenylketonuria (PKU) or those with rare hereditary problems of galactose or lactose intolerance. Furthermore, the drug is contraindicated in patients with functional ileus or confirmed intestinal obstruction.

Age-Specific Eligibility

Phloroglucinol Mylan is approved for use in adults and children over 2 years of age. Efficacy in children under 2 years of age is officially stated as not established by regulatory authorities.

Pregnancy and Lactation Status

Use during pregnancy should only be considered if necessary. In the absence of data, regulatory labeling states that it is advisable to avoid using the medicine while breastfeeding. Additionally, use should be avoided when co-administered with morphine or morphine derivatives due to potential antagonistic effects.

Interactions with other medicines and products

Phloroglucinol's interaction profile, as documented in regulatory information, primarily focuses on a critical drug-drug interaction with certain analgesics.

Contraindicated Combination

Administration of Phloroglucinol Mylan should be avoided in combination with morphine and its derivatives. This restriction is due to a pharmacodynamic conflict where the spasm-inducing effect of the opioid analgesics directly counters the antispasmodic effect of Phloroglucinol. Co-administration would therefore reduce the intended efficacy of Phloroglucinol Mylan.

Pharmacokinetic Considerations

The drug is principally biotransformed in the liver through glucuronic acid conjugation. Regulatory documents do not explicitly detail specific interactions involving CYP450 enzymes, P-glycoprotein, or other major drug transporters that significantly alter Phloroglucinol exposure (AUC/Cmax) when co-administered with other common medications.

Other Interaction Notes

No clinically significant interactions requiring dosage adjustment, timing separation, or specific precautions have been explicitly documented in official regulatory labeling concerning food, alcohol, or common herbal supplements. Furthermore, the official labeling does not include specific population-dependent interaction considerations for individuals with hepatic or renal impairment.

Phloroglucinol functions as a direct musculotropic antispasmodic agent, primarily targeting the smooth muscle cells of the gastrointestinal, biliary, urinary, and uterine tracts. Its mechanism of action involves the modification of intracellular calcium concentration dynamics, which directly influences muscle contractility. The molecule is postulated to act as a non-specific inhibitor of voltage-dependent calcium channels located on the smooth muscle cell membrane. The consequence of this interaction is a reduction in the transmembrane influx of extracellular Ca^2+ ions into the cytoplasm. This decrease in intracellular Ca^2+ levels prevents the formation of the calcium-calmodulin complex, thereby inhibiting the activation of myosin light chain kinase (MLCK). The downstream cascade involves reduced phosphorylation of the myosin light chain (MLC) protein. System-level physiological modulation is characterized by a decrease in the force and frequency of spontaneous and induced smooth muscle contractions, leading to a state of myorelaxation across visceral organs.

Administration Routes and Forms

Phloroglucinol Mylan is formulated for administration through several official routes, reflecting its use for symptomatic relief. The active ingredient is available in multiple forms, including 80 mg oral tablets and orodispersible forms. Other available presentations include a 150 mg suppository and an injectable solution, typically 10 mg/mL, for parenteral use. This allows for administration via the oral, sublingual, intravenous (IV), intramuscular (IM), and rectal routes. The parenteral injection (IV or IM) is generally reserved for the initial management of acute, severe episodes in a supervised clinical setting.

Dosing and Frequency Guidelines

Use of the oral form is strictly intermittent and determined by the onset of symptoms, following an as-needed schedule. For adults, the standard acute dose is two 80 mg tablets (160 mg). Dosing is highly constrained by a minimum interval of two hours between administrations, and the total daily intake must not exceed a maximum of six tablets (480 mg) in a 24-hour period.

Preparation and Age-Specific Rules

Specific preparation rules apply based on the patient population. For the adult orodispersible tablet, the medicine may be taken sublingually (dissolved under the tongue) or dissolved in a glass of water. However, for administration to children over two years old, the tablet must be dissolved in a glass of water before being consumed. The maximum daily dose for children over two years is limited to two tablets (160 mg) per 24 hours. In line with the intended use, the administration is considered symptomatic, and if the underlying condition persists, treatment reassessment is required.

Phloroglucinol Mylan: Recent Clinical Evidence

This section presents a neutral summary of the available research on Phloroglucinol Mylan, describing what has been studied and what remains an area of active research. The findings described here reflect group patterns observed in research and do not determine whether an individual will respond similarly.

Evidence for Functional Gastrointestinal and Bile Duct Spasms

Research was studied for conditions characterized by fluctuating or episodic manifestations in the digestive and biliary systems. Studies examined various designs, including short-term clinical trials, focusing on patient-reported outcomes describing perceived discomfort and measurements of muscle tone. Pharmacological research describes the action of the compound was evaluated in studies focusing on smooth muscle tissue.

Evidence for Acute Painful Spasmodic Urinary Tract Problems

Research was evaluated in clinical trials, including randomized studies, to explore short-term symptom changes in patients experiencing conditions involving periods of heightened symptoms, such as acute renal colic. Studies monitored outcomes related to episodic or acute changes, primarily focusing on reported pain levels and the use of additional pain medication.

Evidence for Painful Spasmodic Gynaecological Conditions and Pregnancy-Related Use

Research was studied for conditions where symptoms may vary in intensity in the gynaecological system. Regulatory guidance and product summaries describe the drug’s application in the context of temporary, acute discomfort associated with these conditions. Research that was applied in studies examining patient-reported experiences in these contexts found that findings describe patterns observed in the studies related to symptom changes.

Long-Term Research and Follow-up Duration

Research has been primarily relevant in trials assessing short-term or episodic symptom patterns, focusing on the management of acute flare-ups. This means that long-term effects are not fully established. There is limited information for long-term outcomes regarding the sustained effects or safety profile when the medication was observed in patients for extended periods of use. For most patient groups, the data for certain groups remain insufficient.

Key Studies & References

1. Package leaflet: Information for the patient Phloroglucinol ELC 80 mg orodispersible tablets phloroglucinol dihydrat - Malta Medicines Authority (Regulatory Document)

Common questions about Phloroglucinol Mylan (FAQ)

Q: How quickly can I expect Phloroglucinol Mylan to start working?

Official pharmacokinetic studies describe how the drug is processed in the body. These studies indicate that maximum concentrations in the bloodstream are typically reached within 15 to 20 minutes after taking the oral form. This data provides an estimate of how quickly the substance becomes available to act in the body.

Q: How long does the effect of one dose of Phloroglucinol Mylan typically last?

The duration the medicine is active in the body is estimated using its half-life, which is the time needed for half of the substance to be eliminated. Official information states the half-life for phloroglucinol is approximately 1 hour and 40 minutes.

Q: What are the most commonly reported side effects of Phloroglucinol Mylan?

According to official safety information, adverse effects are classified by how often they occur. A common side effect reported in clinical experience is a rash (a skin eruption). Other serious but rare reactions are also documented; it is important to refer to the patient information leaflet for the complete list of adverse effects.

Q: Is it normal to feel slightly dizzy after taking Phloroglucinol Mylan?

Dizziness is not explicitly listed in the official regulatory documents as an undesirable effect with a known frequency classification. The regulatory safety profile documents adverse reactions mainly focused on the skin and immune system. Patients are encouraged to review the full patient information leaflet for the most detailed information on known side effects.

Q: Can Phloroglucinol Mylan cause stomach upset or nausea?

According to the official regulatory safety profile, common issues like stomach upset or nausea are not explicitly listed as undesirable effects with a known frequency. The documented adverse reactions focus mainly on potential hypersensitivity events.

Q: Is there a warning about Phloroglucinol Mylan causing dry mouth?

Official safety documentation does not explicitly list dry mouth as an undesirable effect with a known frequency classification. Patients are advised to review the patient information leaflet for any symptoms experienced.

Q: Does Phloroglucinol Mylan interact with regular over-the-counter paracetamol?

Official regulatory labeling explicitly mentions avoiding combination only with morphine and its derivatives because they counteract the antispasmodic effect. Other specific drug-drug interactions, such as with paracetamol (acetaminophen), are not explicitly detailed in the official documents.

Q: Is it safe to drink coffee or caffeine while using Phloroglucinol Mylan?

Regulatory documents state that no clinically significant interactions concerning food, alcohol, or common herbal supplements have been explicitly documented. However, the specific interaction with coffee or caffeine is not specifically addressed in the regulatory notes.

Q: Is Phloroglucinol Mylan generally considered safe for use during pregnancy?

Official regulatory guidance advises that use during pregnancy should only be considered when absolutely necessary. Studies in animals have not indicated any harmful effects. Any decision regarding treatment must be based on an individual assessment by a healthcare provider.

Q: Is Phloroglucinol Mylan a prescription-only drug in most places?

The regulatory classification of Phloroglucinol Mylan as a prescription-only or over-the-counter medicine often varies by country and its local regulatory body. The status is determined locally; patients should check the packaging or consult a local pharmacist for the classification in their specific area.

Q: Is it better to take Phloroglucinol Mylan with or without food?

Pharmacokinetic research indicates that taking the medicine with or without food does not affect the absorption of the drug into the body. This suggests flexibility in how the oral tablet may be taken.

Q: What happens if I accidentally forget to take a dose of Phloroglucinol Mylan?

The official Patient Information Leaflet advises that if a dose is forgotten, it can be taken when remembered, unless it is almost time for your next scheduled dose. The official Patient Information Leaflet advises that the patient should not take a double dose to compensate for a missed one.

Q: What should I do if the medicine does not seem to be working for me?

Since this medicine is used for symptomatic relief, the official guidance states that if symptoms persist or the condition worsens while taking it, the treatment should be reassessed by a healthcare professional.

Q: Can Phloroglucinol Mylan affect my ability to drive or operate machinery?

Official regulatory documents confirm that this medicine has no or negligible influence on the ability to safely drive or operate heavy machinery. This statement is based on the drug's known mechanism and safety profile.

Q: What are the inactive ingredients in Phloroglucinol Mylan tablets?

The tablet contains the active ingredient phloroglucinol along with several inactive ingredients (excipients). According to product information, these may include substances such as lactose monohydrate, aspartame (E951), and magnesium stearate. These components are important to note due to potential contraindications for conditions like phenylketonuria (PKU).

Q: What does the 'Mylan' part of the name indicate?

The name Phloroglucinol is the generic name for the active ingredient. The 'Mylan' part of the name indicates the pharmaceutical company (a brand name) that manufactures and markets this specific version of the medicine.

Storage Requirements

The medicinal product must be stored below 30 C and protected from moisture and light.

To ensure product stability, Phloroglucinol Mylan must be kept in its original package (blister) or, if in a bottle presentation, the container must be kept tightly closed.

For safety, the medicine must be kept out of the sight and reach of children.

Disposal Instructions

Unused or expired Phloroglucinol Mylan must be disposed of according to local requirements for pharmaceutical waste.

Medicines should not be disposed of via wastewater or household waste to prevent environmental contamination.